New 'Off-the-Shelf' cell therapy tested for aggressive lymphomas
NCT ID NCT07316920
Summary
This is an early-stage study to test the safety and initial effectiveness of a new cell therapy called RN1701 for people with B-cell lymphoma that has come back or not responded to other treatments. Up to 19 participants will receive the therapy, which involves immune cells engineered to target cancer. The main goal is to find a safe dose and see if the treatment is feasible, while also checking for early signs that it might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Jiangsu University
Zhenjiang, Jiangsu, 212001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.